NCT00223990View on ClinicalTrials.gov

Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

April 8, 2005

Primary Completion Date

April 26, 2006

Study Completion Date

June 30, 2007

Conditions
Malaria, Falciparum
Interventions
BIOLOGICAL

FMP1/AS02A

FMP1/AS02A candidate malaria vaccine

BIOLOGICAL

RabAvert

RabAvert rabies vaccine

Trial Locations (1)

Unknown

Walter Reed Project, Kombewa Clinic, Kisumu

Sponsors
All Listed Sponsors
collaborator

The PATH Malaria Vaccine Initiative (MVI)

OTHER

collaborator

United States Agency for International Development (USAID)

FED

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Kenya Medical Research Institute

OTHER

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED